Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

•The increase in DMTs for MS complicates the decisions on initial and subsequent therapies for each patient.•This article collates 99 clinically relevant statements agreed by 25 experts on treatment switching approaches in RMS.•The statements cover treatment objectives, reasons for DMT switching, su...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2022-07, Vol.63, p.103805-103805, Article 103805
Hauptverfasser:	Brieva, Luis, Estruch, Bonaventura Casanova, Merino, Juan Antonio García, Meca-Lallana, Virginia, Río, Jordi, Rodríguez-Antigüedad, Alfredo, Agüera, Eduardo, Ara, Jose Ramón, Luque, Adrián Arés, Garcia, Carmen Arnal, Blanco, Yolanda, Castillo-Triviño, Tamara, Costa-Frossard, Lucienne, González Platas, Montserrat, Pascual, Lamberto Landete, Llaneza-González, Miguel, Ginés, María Luisa Martínez, Matías-Guiu, Jorge, Meca-Lallana, José E, Bilbao, Mar Mendibe, Sempere, Angel Pérez, Romero-Pinel, Lucia, Saiz, Albert, Moral, Ester
Format:	Artikel
Sprache:	eng
Schlagworte:	Benefit-risk Disease modifying therapy Relapse Relapsing multiple sclerosis Therapy switching Washout period
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!